From a clinical standpoint, the message is clear: - Yes to metabolic monitoring - Yes to awareness of glycemic risk - But no to avoiding statins out of fear of diabetes, especially in patients at high cardiovascular risk The real question isnt: Do statins cause diabetes? but rather: Does cardiovascular benefit outweigh metabolic risk? And once again, the answer is: yes
Are GLP-1s covered by Medicare
Pricing depends on required laboratory testing frequency, medication selection, and additional services like body composition analysis or nutritional counseling sessions
However, a number of 503A pharmacies continued compounding GLP-1 products, taking care to demonstrate that their preparations were not essentially a copy of the FDA-approved versions
Dosing & Protocol One Medication
Later dose increases build on existing tolerance